There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Diebold Nixdorf Incorporated (DBD) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.12, or 6.98%, to $1.84. The Diebold Nixdorf Incorporated has recorded 6,545 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Diebold Nixdorf Closes Transactions with Key Financial Stakeholders to Support Debt Refinancing.
This NYSE-listed company operates within the Software – Application industry segment, falling under the Technology sector. At the end of the last regular session, the stock closed at $1.72 and fluctuated between $1.7300 as its day high and $1.6200 as its day low. The current market capitalization of Diebold Nixdorf Incorporated is $126.47M. A total of 0.69 million shares were traded on the day, compared to an average of 1.84M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, DBD has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 60 BUYs and 25 SELLs from insiders. Insiders purchased 1,990,785 shares during that period but sold 312,863.
In the most recent transaction, COSTELLO ELLEN bought 12,000 shares of DBD for 3.29 per share on May 17. After the transaction, the Director now owns 166,283 company shares. In a previous transaction on May 16, BESANKO BRUCE H bought 7,152 shares at 3.50 per share. DBD shares that Director owns now total 100,726.
Among the insiders who bought shares, RUTHERFORD JEFFREY L acquired of 14,784 shares on May 13 at a per-share price of $3.40. This resulted in the EVP and CFO holding 447,340 shares of DBD after the transaction. In another insider transaction, Anton Arthur F bought 100,000 shares at $2.93 per share on May 12. Company shares held by the Director now total 271,677.
The income generated by dividends is an indication that a company is improving its financial position, which is why investors prefer companies paying dividends. DBD’s most recent ex-dividend date was 2/23/2018 when it declared a $0.10 quarterly dividend that was paid in cash on 3/16/2018. Previously, the company paid the dividend on 12/8/2017 with an ex-dividend date of 11/16/2017. The DBD stock dividend was $0.10 per share in cash.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for DBD in the last 3 months, the mean price target is $4.00 with high estimates of $5.00 and low estimates of $3.00. In terms of 52-week highs and lows, DBD has a high of $11.00 and a low of $1.26.
As of this writing, DBD has an earnings estimate of $0.24 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $0.35 per share and a lower estimate of $0.06. The company reported an EPS of -$1.61 in the last quarter, which was -666.70% lower than expectations of -$0.21.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DBD is Overweight with a score of 3.00. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 3 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.